drugset / Trial / NCT05169021

Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD

NCT05169021

Phase 4 Not yet recruiting 15000 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

The primary objectives of this trial are: 1. Efficacy evaluation of amlodipine folic acid tablets: To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing all-cause stroke in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level. 2. Intensive Antihypertensive Therapy: To assess the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of combined cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level, using two basic anti-hypertensive drugs, amlodipine tablets 5 mg or amlodipine folic acid tablets 5.8 mg.

Timeline

Start
2021-12-31
Primary completion
2024-12-31
Completion
2028-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Comparator folic acid Other / unclassified 0.8 mg
Comparator Candesartan Unknown 4 mg
Comparator Candesartan Unknown 8 mg
Comparator Indapamide Small molecule 2.5 mg

Indications